Navigation Links
Phase III Study Shows Once-Daily NVA237 is Superior to Placebo and Similar to Tiotropium in Improving Lung Function in COPD
Date:6/30/2011

VA149; the combination of NVA237 with Novartis' once-daily, long-acting beta2-agonist (LABA), indacaterol, is planned for 2013.  Indacaterol is now approved in more than 50 countries and available in more than 20, with US approval dependent on an FDA decision expected in July 2011. 

Notes for Editors:

About COPD

COPD is a chronic obstruction of the airways which affects 210 million people worldwide[1] and is projected to be the third leading cause of death by 2020[2].  It is a progressive lung disease with symptoms including chronic bronchitis and/or emphysema, which slowly progresses and eventually leads to a largely irreversible loss of lung function.  While there is no cure, bronchodilators such as LAMAs and LABAs make breathing easier by enlarging the patient's airways, and are recognised in international guidelines as an integral part of the treatment for COPD.

About Sosei

Sosei is an international biopharmaceutical company anchored in Japan with a global reach. It practises a reduced risk business model by acquiring compounds from, and bringing compounds into, Japan through exploitation of its unique position within global markets.

For further information about Sosei, please visit http://www.sosei.com/.

Forward-Looking Statements

This press release contains "forward-looking statements", including statements about the discovery, development and commercialisation of products. Various risks may cause Sosei's actual results to differ materially from those expressed or implied by the forward-looking statements, including adverse results in clinical development programmes; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialise products and serv
'/>"/>

SOURCE Sosei Group Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. DNA Medicine Institute Awarded Two Phase III SBIR NASA Contracts for Its rHEALTH Sensor
2. Phase I of the Swedish/Issaquah Medical Center Campus to Open in July
3. The Lancet Publishes Data from Protege, MacroGenics Phase 3 Clinical Study of Teplizumab in Type 1 Diabetes Patients
4. Morphotek®, Inc. Announces Initiation of Farletuzumab Phase II Study in First-Line Treatment of Non-Small Cell Lung Cancer
5. Palatin Technologies, Inc. Initiates Enrollment in Phase 2b Trial With Bremelanotide in Women With Female Sexual Dysfunction
6. Cardium Announces Plans to Acquire Transdel Pharmaceuticals Phase 3 Topical Analgesic and Cosmeceutical Business Assets
7. Glycotex, Inc. Releases Final Phase II Clinical Trials Results in the Clinicaltrials.gov Database and Announces the Results of the Mechanism of Action Study for its Product Candidate GLYC-101
8. Ampio Pharmaceuticals, Inc. Releases Results From Phase III Clinical Trial of Zertane™ for the Treatment of Premature Ejaculation (PE), the Most Prevalent Form of Male Sexual Dysfunction
9. Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
10. Once-Monthly Exenatide Improved Glucose Control in Patients with Type 2 Diabetes: Phase 2 Study Results Presented at ADA 2011
11. New Phase 2 Data Published in New England Journal of Medicine Show Bardoxolone Methyl Sustained Improvement in Measure of Kidney Function (eGFR) Over 52 Weeks in Patients With Moderate to Severe Chronic Kidney Disease and Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... N.J. , May 4, 2015 Thirty-six ... percent seek help. During May – National Hearing Month ... loss could be missing out on the sounds of ... the trees. To ensure that you won,t ... that color our world, Oticon, Inc. offers practical advice: ...
(Date:5/4/2015)... WORCESTER, Mass. and TORONTO ... ( www.generex.com ) (OTCQB:GNBT) today announced that it intends ... securities it receives upon completion of a definitive licensing ... to Smoofi, Inc. ( www.smoofi.com ) (OTCQB:SMFI). ... a non-binding letter of intent in respect of the ...
(Date:5/4/2015)... , May 4, 2015 RadiologyAuction will have their ... video and product demonstrations at the end of the ... such as Kodak and Fuji Cr,s, Agfa and Sony, ... the first event. Various imaging equipment will be available ... After years of buying and selling imaging ...
Breaking Medicine Technology:It's Better Hearing Month 2Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 2Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 3Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 4Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 5RadiologyAuction Announces Event Starting On May 5th 2
... 16, Uroplasty, Inc. (Nasdaq: UPI ), ... innovative proprietary products to treat voiding dysfunctions, announced today ... Jiwani, Uroplasty,s Vice President and CFO, will present the ... Hunter Securities Inaugural Healthcare Conference at 3:30  PM PDT ...
... a crippling disease worldwide, with an estimated eight million sufferers ... a suit of rusty armour," with unrelenting, razor-like pain. ... reverse the degenerative condition. However a discovery made ... hold the key to not only halting the degenerative process, ...
Cached Medicine Technology:Uroplasty to Present at Global Hunter Securities Inaugural Healthcare Conference 2New Hope For Joint Pain Sufferers 2New Hope For Joint Pain Sufferers 3
(Date:5/4/2015)... LiveSchool ” was featured on NewsWatch as part of ... latest and coolest applications on the market for iOS, ... and technology expert, conducted the app review and shared ... students with good behavior. , Positive re-enforcement is more ... And the good people at LiveSchool have taken note ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 The opportunity for ... full life are the motivating forces behind The Fairy Godmother ... psychologist and author Amy L. Stark. , The inspiration for ... girl next door comes from Stark’s desire to be a ... been a fairy godmother to my neighbors’ children since they ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 The U.S. ... baby boomers join the ranks of senior citizens (1) ... on an already over-burdened healthcare system. Additionally, as older ... to replace them. Per the U.S. Census Bureau, the ... to increase 75% by 2050 while those 25 to ...
(Date:5/4/2015)... OK and Seattle, WA (PRWEB) May 04, 2015 ... the formation of a collaboration to facilitate development of ... of ophthalmic disorders that lead to blindness, including Diabetic ... the MiDROPS™ formulation platform developed by EyeCRO, which can ... eye via a topical eyedrop. , Under the ...
(Date:5/4/2015)... 04, 2015 New findings released today ... Association (ABTA) show that people diagnosed with a brain ... options, including clinical trials, at the time of diagnosis, ... difficult decisions about their course of treatment. The release ... first nationwide brain tumor volunteer network, the ABTA CommYOUnity™, ...
Breaking Medicine News(10 mins):Health News:An Application for Teachers to Reward Students with Good Behavior Was Featured on NewsWatch Television 2Health News:Introducing New Children’s Book The Fairy Godmother Next Door 2Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 2Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 3Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 4Health News:EyeCRO and NeuMedics Announce Collaboration to Utilize MiDROPS™ Technology for the Development of NM108 2Health News:EyeCRO and NeuMedics Announce Collaboration to Utilize MiDROPS™ Technology for the Development of NM108 3Health News:American Brain Tumor Association Poll Underscores Need for Greater Awareness and Education at Time of Diagnosis 2Health News:American Brain Tumor Association Poll Underscores Need for Greater Awareness and Education at Time of Diagnosis 3
... Highlights, - Revenue for the first quarter was $480.6 million, up 7.6% from ... ... ("FOI") grew 7.2% for the twelve, months ended March 31, 2008 over ... was $38.6 million, or $0.38,per outstanding common share, a 19% increase over the ...
... project as innovative in terms of energy efficiency and ... awarded nearly $27 million in funding for a new ... (USC). USC was one of 12 California institutions considered ... million to build stem cell research facilities throughout California. ...
... May 8, 2008 at 2:00 pm ET, MISSION ... ENSG ), the parent company of the Ensign(TM) ... today reported results for the first quarter of fiscal ... ) Highlights of the First Quarter Include:, ...
... 7 Conseco, Inc. (NYSE: CNO ),today reported ... set a new quarterly sales record with an increase ... Prieur said. "This performance included,an 11% increase at Bankers ... increase in total sales including new product offerings) of ...
... , Ottawa (May 7, 2008) The Honourable ... the Canadian Institutes of Health Research (CIHR) for 764 ... Minister Clement was joined by Dr. Patrick McGrath, a ... neonatologist and CIHR-funded researcher from the University of Alberta, ...
... 7 Dr. Hugo Stephenson, founder and ... drug safety, today,presented new insight about the ... the U.S. Food and Drug Administration (FDA). ... (rosuvastatin),Lipitor (atorvastatin), and Zocor (simvastatin) all warn ...
Cached Medicine News:Health News:Brookdale Announces First Quarter 2008 Results 2Health News:Brookdale Announces First Quarter 2008 Results 3Health News:Brookdale Announces First Quarter 2008 Results 4Health News:Brookdale Announces First Quarter 2008 Results 5Health News:Brookdale Announces First Quarter 2008 Results 6Health News:Brookdale Announces First Quarter 2008 Results 7Health News:Brookdale Announces First Quarter 2008 Results 8Health News:Brookdale Announces First Quarter 2008 Results 9Health News:Brookdale Announces First Quarter 2008 Results 10Health News:Brookdale Announces First Quarter 2008 Results 11Health News:Brookdale Announces First Quarter 2008 Results 12Health News:Brookdale Announces First Quarter 2008 Results 13Health News:Brookdale Announces First Quarter 2008 Results 14Health News:Brookdale Announces First Quarter 2008 Results 15Health News:Brookdale Announces First Quarter 2008 Results 16Health News:Brookdale Announces First Quarter 2008 Results 17Health News:Brookdale Announces First Quarter 2008 Results 18Health News:Brookdale Announces First Quarter 2008 Results 19Health News:Brookdale Announces First Quarter 2008 Results 20Health News:Brookdale Announces First Quarter 2008 Results 21Health News:Brookdale Announces First Quarter 2008 Results 22Health News:USC receives nearly $27 million in funding for new stem cell research facility 2Health News:The Ensign Group, Inc. Reports First Quarter 2008 Earnings 2Health News:The Ensign Group, Inc. Reports First Quarter 2008 Earnings 3Health News:The Ensign Group, Inc. Reports First Quarter 2008 Earnings 4Health News:The Ensign Group, Inc. Reports First Quarter 2008 Earnings 5Health News:The Ensign Group, Inc. Reports First Quarter 2008 Earnings 6Health News:The Ensign Group, Inc. Reports First Quarter 2008 Earnings 7Health News:The Ensign Group, Inc. Reports First Quarter 2008 Earnings 8Health News:The Ensign Group, Inc. Reports First Quarter 2008 Earnings 9Health News:The Ensign Group, Inc. Reports First Quarter 2008 Earnings 10Health News:Conseco Reports First Quarter Results 2Health News:Conseco Reports First Quarter Results 3Health News:Conseco Reports First Quarter Results 4Health News:Conseco Reports First Quarter Results 5
Pocket-sized instrument, powered by two AA-sized alkaline batteries. Built-in throat illuminator, rectangular viewing lens for instrumentation under magnification....
The Pneumatic Consulting Otoscope provides two viewing lenses for dual observation of the tympanic membrane. Sealed system for pneumnatic otoscopy and rotatable head for left- and right-sided viewin...
Provides 30% more magnification and twice the field of view. Adjustable focus, with insufflator bulb....
... to laser treatment of AMD patients ... compares to the Opal Photoactivator from,Lumenis. ... (verteporfin for injection) therapy, the Opal ... any other laserfeatures,that ensure the highest ...
Medicine Products: